In episode 447, Mike and James invite Tina and Mike to talk about a really important topic – is there asymptomatic transmission of COVID-19? The simple answer is yes. Have a listen and hear about all the data and the numbers.
Show notes
Tools for Practice
In episode 446, Mike and James invite Mike and Tina to talk about all things COVID. In this podcast we look at what are the presenting symptoms, the clinical course and the risk factors for mortality.
Show notes
Tools for Practice
In episode 445, Mike and James wade into the evidence-free zone (pretty much) around assessing dyspnea over a telephone/video conference. We talk about the Roth score, respiratory rate, fever, and patient self-rating of dyspnea. Have a listen and see what we found.
Show notes
The BMJ
In episode 444, James and Mike wade into the evidence quagmire around hydroxychloroquine and COVID-19. The bottom line is the evidence will likely be different around the time you listen to the podcast. So listen quickly.
Show notes
1)Tools for Practice
Hydroxychloroquine with or without azithromycin for COVID-19
2) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
In episode 443, James and Mike continue with Mike Kolber and we discuss the evidence around electronic cigarettes and their use for smoking cessation. Overall, the podcast ends up being smoking hot in so many ways.
Show notes
Tools for Practice
Electronic Cigarettes – Hoot that helps, hurts, or just hype?
In episode 442, James and Mike welcome back Mike Kolber to discuss all the evidence around biosimilars. The issue is exactly the same one we have had for decades with the question around brand name versus generic medications. Tune in and find out the answer.
Show notes
Tools for Practice
It’s all in the details… or is it? Biosimilars versus biologics for inflammatory conditions
In episode 441, James and Mike revisit the problem with guidelines. We talk about recent writings on the issues around guidelines. We discuss the main problems and believe it or not we give advice and suggestions for how to make them better.
Show notes
1) Health Affair
Fixing Clinical Practice Guidelines
2) Evidence vs Consensus in Clinical Practice Guidelines
JAMA 2019 Jul 19. doi: 10.1001/jama.2019.9751
3) The future of guidelines: Primary care focused, patient oriented, evidence based and simplified
In episode 440, Mike and James yet again invite Adrienne to go over all the evidence for treating toenail onychomycosis. We find that ~ 40% more people get better on oral treatments than on placebo. For topicals the number is closer to 10%. Topicals should likely only be used if there is <40% nail involvement.
Show notes
Tools For Practice
In episode 439, Mike and James invite Adrienne to take us through the impressively large amount of evidence for the PDE5 inhibitors for erectile dysfunction. We find that the NNTs are 2-3 for the not clearly defined endpoint of successful intercourse. There is a 20% absolute increase in adverse effects but almost no one stops using these medications because of these effects. Go figure.
Show notes
Tools For Practice
Taking a hard look at the evidence: Phosphodiesterase-5- inhibitors in erectile dysfunction
In episode 438, Mike and James discuss 4 studies that likely could change what you are doing, or saying to your patients in your practice. Hip replacements – they last longer than you may think, vitamin D – bigger isn’t better, actinic keratosis – 5-FU is best, and weight loss really does treat T2DM. Check it out.
Show notes
THE NUTRITION PROPOSITION BOOK
Check it out at nutritionproposition.com and think about picking up a copy on Amazon. All the evidence you ever wanted about nutrition and the only nutrition book that won’t tell you what to eat.
